Headlands Research Acquires AMCR Institute
Headlands Research has announced the acquisition of AMCR Institute, which has been in operation for more than 20 years. The site’s team brings experience in metabolic, endocrine, and medical device research to the growing clinical research site network.
Led by principal investigator (PI) Timothy S. Bailey, MD, FACE, FACP, CPR, the San Diego–based clinical research site specializes in metabolic, endocrine, and other chronic conditions such as type 1 and type 2 diabetes and obesity. Bailey is a board-certified endocrinologist and is certified by the Association of Clinical Research Professionals (ACRP). He and his staff have worked with thousands of volunteers in Phase I-IV trials and have extensive experience with the evaluation of medical devices such as continuous glucose monitors (CGMs).
The acquisition of AMCR Institute, now known as Headlands Research AMCR Institute, is the most recent as the company expands its clinical research site network to support more clinical trials and provide access to investigational therapies to a diverse, representative population. Headlands Research recently launched one new clinical research site and acquired two additional established sites: Headlands Research Detroit serves multiple therapeutic areas, including Alzheimer’s disease and vaccines; Headlands Research Eastern Massachusetts specializes in neurodegenerative diseases such as Alzheimer’s disease, and Clinvest Research specializes in chronic diseases including migraine and arthritis.
Reference
Headlands Research Acquires AMCR Institute, Adding Medical Device Expertise to the Clinical Research Site Network. (2023, July 27). Business Wire.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
